Biologics Not Working for Your Arthritis? Here Is What Most Patients Do Next

At a Glance:

• A substantial proportion of arthritis patients do not achieve their treatment targets with their first biologic
• Biologics target inflammatory immune pathways — they are not designed to directly supply the structural building blocks for cartilage or extracellular matrix repair
• Transdermal glucosamine supplementation addresses the structural joint tissue component through a different mechanism entirely
• URAH is designed to support the target joint first — delivering to the tissues beneath the application site before entering broader circulation

You started biologics with real hope. The injections, the infusions, the immune suppression — you accepted all of it because the alternative felt worse. But weeks passed. Then months. And the results were not what you or your doctor expected.

If that is where you are, you are not alone — and you are not failing your treatment. Your treatment may be failing you.

How We Evaluated the Evidence

This article draws on peer-reviewed clinical studies, published meta-analyses, and guidelines from major rheumatology bodies including the American College of Rheumatology and Arthritis Foundation. Clinical evidence was weighted most heavily. We also reviewed the published research on transdermal glucosamine supplementation, including the only product-specific peer-reviewed study we identified for URAH reporting changes in measured joint space width.

Where we describe biologic outcomes, we are reporting documented clinical findings — not making claims about any individual patient's experience.

The Statistic Your Rheumatologist May Not Have Mentioned

A substantial proportion of patients with rheumatoid arthritis who were previously naïve to biologic disease-modifying anti-rheumatic drugs did not achieve their treatment targets with their first biologic during one year of follow-up, according to research published in PLOS One.

That is not a fringe outcome. It is a documented, widely observed clinical reality.

In a meta-analysis examining sequential biologic therapy, secondary non-response — where a biologic works initially and then stops — prompted switching in approximately 35% to 52% of cases. (Clinical Rheumatology, 2025)

A UK regional audit found that lack of effect was the most common reason patients discontinued a biologic drug, accounting for 67% of discontinuations. (PMC, 2014)

The reality is that biologics are powerful and genuinely transformative for some patients — and genuinely disappointing for many others. Understanding why, and what comes next, is what this article is for.

Why Biologics Sometimes Fail

Biologics work by blocking specific proteins in the immune system — TNF, interleukins, T-cell activity — that drive inflammation in autoimmune conditions like rheumatoid arthritis and psoriatic arthritis. When they work, they work well. When they do not, the reasons tend to fall into three categories.

Primary non-response — the biologic never worked to begin with. Your immune system's inflammatory pathways may not be driven primarily by the protein the drug targets.

Secondary non-response — it worked for a period, then stopped. The American College of Rheumatology recommends that patients who have not reached their treatment target might be better off switching to a drug with a different mechanism of action rather than trying a second drug in the same class.

Intolerable side effects — the drug may be working on inflammation but the cost to immune function or daily quality of life is too high to sustain. All biologics suppress the immune system and increase the risk of infections, including upper respiratory infections, pneumonia, urinary tract infections, and opportunistic infections such as tuberculosis and hepatitis B. (Arthritis-health)

None of these outcomes mean your condition is untreatable. They mean the specific intervention did not match your specific biology.

The Structural Gap Biologics Are Not Designed to Fill

Here is something that does not get enough attention — even when biologics are working effectively.

Biologics primarily target inflammatory signalling pathways. They are not designed to directly supply the structural building blocks for cartilage, glycosaminoglycans, or extracellular matrix repair. Controlling inflammation can indirectly slow structural damage — and that matters enormously in autoimmune arthritis. But it is a different mechanism from directly supporting the tissue repair and maintenance pathways that cartilage depends on.

As the Arthritis Foundation states, biologics "may slow or stop inflammation that can damage joints" — slowing damage and actively supplying structural repair substrates are different biological functions.

The glycosaminoglycans that give cartilage its structure and hydration, the hyaluronic acid that lubricates the joint, the extracellular matrix that collagen fibres are embedded in — these depend on a continuous supply of structural precursors that the body uses to synthesise and maintain them. That synthesis pathway is separate from the inflammatory mechanism biologics address.

This is why many patients on biologics — even those whose inflammation is well-controlled — still experience progressive joint stiffness and structural deterioration over time. The immune driver may be managed. The structural maintenance pathway still needs support.

The Difference Between Systemic and Localised-First Supplementation

Most joint supplements work systemically. You swallow them, they enter your bloodstream, and your body distributes them wherever it decides — with no mechanism to prioritise the joint under stress.

Oral glucosamine, for example, is a precursor to multiple glycosaminoglycans — including hyaluronic acid, chondroitin sulfate, keratan sulfate, and other extracellular matrix components involved in cartilage and joint tissue health. The molecule itself is valuable. The delivery method is the limitation. By the time it has cleared the digestive system and liver and entered systemic circulation, it distributes throughout the entire body rather than concentrating at your knee or your thumb or your wrist.

Read: Why oral glucosamine often disappoints → https://umicellar.com/blogs/relief-without-surgery/why-glucosamine-pills-dont-work-for-joint-pain-and-what-actually-does

URAH Micellar Glucosamine works differently. Applied directly over the affected joint, the micellar technology is designed to support the tissues directly beneath the application site first — before the compound enters broader circulation. You are not supplementing your whole body and hoping the right molecules find the right place. You are directing support to the joint that needs it most, first.

Apply it over your knee. Your thumb. Your wrist. The target gets priority.

What the Research Shows

An independent peer-reviewed study published in the Hong Kong Physiotherapy Journal (2018, Vol. 38, No.1) tracked Joint Space Width — a clinical marker of cartilage thickness measured by imaging — in participants using URAH Micellar Glucosamine transdermally over 12 weeks. Results from this single study, conducted at two university teaching hospitals, showed a 61% increase in measured joint space width, from 0.49mm to 0.79mm. These are preliminary findings from one research centre, not yet independently replicated — but they represent the only product-specific peer-reviewed study we identified reporting changes in measured joint space width for a transdermal glucosamine supplement.

A separate study published in UK BMC Research Notes (2016) reported substantially higher tissue absorption for micellar glucosamine compared with oral formulations — providing a mechanistic basis for why targeted delivery may produce results that oral supplements do not.

URAH delivers 8% micellar glucosamine + MSM. It is manufactured to GMP pharmaceutical standards, has been recommended by healthcare professionals for over a decade, and has been used by over one million people worldwide.

Some users report noticing a difference within 30 minutes of first application. For joint deterioration that has been developing over months or years — as is common when patients have been on biologics — many users report noticeable improvements within several weeks of consistent use. Individual results vary. Structural support builds over 12 weeks of consistent daily application.

Who This Article Is Most Relevant For

⚠️ Important for RA, Psoriatic Arthritis, and Ankylosing Spondylitis Patients: Never discontinue or modify your prescribed biologic therapy without consulting your rheumatologist. URAH is a structural joint support supplement and is not a substitute for immune-modifying medical treatment. If you are managing an autoimmune arthritis condition, always coordinate with your healthcare team before adding any supplement.

URAH addresses the structural joint tissue component — the glycosaminoglycan and extracellular matrix maintenance pathway — which is separate from and complementary to the immune mechanism that biologics target.

A 60-Day Risk-Free Way to Find Out

For patients who have been through the biologic experience — the hope, the waiting, the disappointment — a well-evidenced supplement option that addresses the structural component biologics are not designed to fill is worth exploring at low risk.

URAH ships internationally and comes with a 60-day money-back guarantee. If you are not satisfied with the results, return it for a full refund. No questions asked.

Explore URAH Transdermal Glucosamine → https://umicellar.com/collections/sporting-cream-msm

At an affordable monthly cost, with a 60-day guarantee — the risk of trying is low. The potential benefit is significant.

Frequently Asked Questions

What does it mean when a biologic fails? Biologic failure refers to a situation where a patient does not achieve their treatment target — which may mean insufficient symptom control, disease progression despite treatment, intolerable side effects, or a loss of response over time. Research shows this is a common outcome, particularly with first biologics. It does not mean the condition is untreatable — it typically means a different approach or combination is needed.

Why is my biologic not working? The most common reasons are primary non-response, secondary non-response where the immune system adapts over time, or side effects that make the treatment unsustainable. Your rheumatologist is the right person to evaluate which applies to your situation.

What do doctors recommend when a biologic fails? The American College of Rheumatology recommends switching to a biologic with a different mechanism of action when the first one fails. Your rheumatologist will guide this decision based on your specific disease activity, history, and preferences.

Can supplements help when biologics are not working? Biologics and joint supplements address different biological mechanisms. Biologics target immune signalling pathways. Transdermal glucosamine supplements like URAH support the structural joint tissue — the glycosaminoglycan matrix and extracellular matrix components — that inflammation damages and biologics are not designed to repair. For many patients, the two are complementary.

What is the difference between URAH and oral glucosamine supplements? Oral glucosamine distributes systemically after digestion. URAH is applied directly over the affected joint, designed to support the target tissues first before entering broader circulation. This localised-first delivery is supported by research showing substantially higher tissue absorption compared with oral formulations.

Does URAH replace medical treatment for arthritis? No. Anyone with diagnosed inflammatory arthritis should continue their medical management under a rheumatologist's care. URAH supports the structural joint tissue component through a complementary mechanism and does not replace biologic therapy in autoimmune arthritis.

Is there a natural alternative to biologics? No supplement replicates the immune-modifying mechanism of biologics in autoimmune arthritis. However, for patients seeking to support the structural joint tissue component — separate from immune management — transdermal glucosamine supplementation addresses a pathway that biologics are not designed to fill, with published peer-reviewed structural evidence.

References

1. Shi Q et al. Inadequate response to first biologic DMARD in RA. PLOS One, 2018. https://doi.org/10.1371/journal.pone.0197654
2. Salieva RS et al. Sequential biologic DMARD therapy in RA. Clinical Rheumatology, 2025. https://www.physiciansweekly.com/post/determining-when-sequential-biologic-therapy-is-effective-for-rheumatoid-arthritis
3. UK Regional Audit. Prescribing and switching of biologic drugs in RA. PMC, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164745/
4. Arthritis Foundation. Biologic drugs for arthritis. https://www.arthritis.org/drug-guide/biologics/biologics
5. Arthritis Foundation. What happens when an anti-TNF fails for RA. https://www.arthritis.org/drug-guide/medication-topics/what-happens-when-an-anti-tnf-fails-for-ra
6. Arthritis-health. Risks and side effects of biologics. https://www.arthritis-health.com/treatment/medications/risks-and-side-effects-biologics
7. American College of Rheumatology. Guideline for treatment of RA, 2021. https://www.rheumatology.org/
8. Onigbinde AT et al. Transdermal glucosamine. Hong Kong Physiotherapy Journal, 2018; 38(1):1–13.
9. BMC Research Notes. Micellar glucosamine absorption. Volume 9, 2016. https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-016-2059-8
10. URAH Clinical Research. https://urah.com.sg/all_clinical_research_paper

Naomi Kim has over 7 years of experience in healthcare, including founding a health startup. She contributes to Umicellar's evidence-based approach to joint health and healthy ageing.